CurrentUnitedHealthcarePolicy IEXD0081.09

Sodium Hyaluronate – Individual Exchange Medical Benefit Drug Policy

UnitedHealthcare Individual Exchange medical benefit drug policy for sodium hyaluronate (hyaluronan) products for intra-articular injections and select other indications; applies to Individual Exchange plans in all states except MA, NV, and NY. Defines medical necessity criteria, diagnosis-specific initial and continuation authorization requirements, products subject to step/change, exclusions (cosmetic), and applicable procedure/drug/diagnosis codes (Part 1 of 2).

Policy Summary

PayerUnitedHealthcare

PolicySodium Hyaluronate – Individual Exchange Medical Benefit Drug Policy

Policy CodePolicy IEXD0081.09

Change TypeRevised HCPCS list / description update

Effective DateJan 1, 2026

Next Review Date

Key ActionMembers on non-preferred products must change therapy to Durolane, Euflexxa, or Gelsyn-3 unless Medical Necessity Criteria are documented.

SourceLink

POLICY UPDATE CHANGES

Updated list of applicable HCPCS codes to reflect annual edits and revised description for J7322.

1Primary covered indication (knee OA)

3Preferred products

11Non-preferred products listed

>=6 monthsReauthorization interval

Skin contouring use stance

Coverage Summary

This Individual Exchange medical benefit drug policy applies to Individual Exchange plans in all states except MA, NV, and NY and takes a mixed coverage stance: the policy supports coverage for intra-articular sodium hyaluronate primarily for knee osteoarthritis when medical necessity and diagnosis-specific criteria are met, while other joint indications are considered unproven and not medically necessary.

The policy designates Durolane, Euflexxa, and Gelsyn-3 as preferred products subject to the Diagnosis-Specific Criteria; a number of other FDA-approved hyaluronate products are treated as non-preferred and require meeting Medical Necessity Criteria (trial/failure or contraindication/intolerance to the preferred products plus physician attestation) to continue coverage or for authorization.

Coverage for sodium hyaluronate is contingent on meeting conservative therapy, functional impairment, contraindication, dosing, and authorization thresholds (e.g., conservative therapy ≥ 3 months, minimum interval between courses ≥ 6 months, and initial/continuation authorization for a single treatment course once per joint for 6 months per FDA labeling).

Policy thresholds & quick facts - sodium hyaluronate

Conservative therapy duration>= 3 months

Minimum interval between courses>= 6 months

Authorization durationSingle treatment course once per joint for 6 months

Preferred products count3 (Durolane, Euflexxa, Gelsyn-3)

Non-preferred products listed11 (Gel-One, GenVisc 850, Hyalgan, Hymovis, Monovisc, Orthovisc, Supartz, Synojoynt, Synvisc/Synvisc-One, Triluron, TriVisc, Visco-3)

Product-specific Requirements & Prior Authorization

Medical Necessity - Product-specific (switch requirement)

{

"operator":"all",

"text":"Medical Necessity - Product-specific (switch requirement): In order to continue coverage, members already receiving non-preferred sodium hyaluronate products (Gel-One, GenVisc 850, Hyalgan, Hymovis, Monovisc, Orthovisc, Supartz, Synojoynt, Synvisc or Synvisc-One, Triluron, TriVisc, Visco-3) will be required to change therapy to a preferred product (Durolane, Euflexxa, or Gelsyn-3) unless the conditions in the child criteria below are met.",

"children":[

{

Initial Therapy Criteria (Knee Osteoarthritis)

Diagnosis-Specific Criteria - Initial Authorization (Sodium Hyaluronate Naïve Patients)

Intra-articular injections of sodium hyaluronate are medically necessary when ALL of the following are met:

ALL of the following

Diagnosis of knee osteoarthritis
The member has not responded adequately to conservative therapy (which may include physical therapy or pharmacotherapy e.g., NSAIDs, acetaminophen and/or topical capsaicin cream) or injection of intra-articular steroids and such therapy has not resulted in functional improvement after at least 3 months, OR the member is unable to tolerate conservative therapy because of adverse side effects>= 3 months
Conservative therapy duration threshold
The member reports pain which interferes with functional activities (e.g., ambulation, prolonged standing)

Continuation / Reauthorization Criteria

Reauthorization/Continuation

Repeated courses may be considered when ALL of the following are met:

ALL of the following

Diagnosis of knee osteoarthritis
Documentation of positive clinical response to prior therapy (e.g., significant pain relief was achieved with the prior course of injections)
Pain has recurred
At least 6 months have passed since the prior course of treatment for the respective joint>= 6 months
Minimum interval between courses

Unproven / Exclusions

Not Medically Necessary / Unproven Indications

Intra-articular injections of sodium hyaluronate are unproven and not medically necessary for indications other than knee OA due to insufficient evidence, including but not limited to:

ANY of the following

Hip osteoarthritis
Temporomandibular joint osteoarthritis
Temporomandibular joint disc displacement

Cosmetic Exclusion

Hyaluronic acid gel preparations for skin appearance are considered cosmetic and not covered when used to:

ALL of the following

Applicable Codes

CPT / Procedure Codes (referential)CPT

20605	Arthrocentesis, aspiration and/or injection, intermediate joint or bursa; without ultrasound guidance
20606	Arthrocentesis, aspiration and/or injection, intermediate joint or bursa; with ultrasound guidance, with permanent recording and reporting
20610	Arthrocentesis, aspiration and/or injection, major joint or bursa; without ultrasound guidance
20611	Arthrocentesis, aspiration and/or injection, major joint or bursa; with ultrasound guidance, with permanent recording and reporting

HCPCS / J-codes (sodium hyaluronate products)HCPCS

J3490	Unclassified drugs
J7318	Hyaluronan or derivative, Durolane, for intra-articular injection, 1 mg
J7320	Hyaluronan or derivative, GenVisc 850, for intra-articular injection, 1 mg
J7321	Hyaluronan or derivative, Hyalgan, Supartz or Visco-3, for intra-articular injection, per dose
J7322	Hyaluronan or derivative, Hymovis or Hymovis One, for intra-articular injection, 1 mg
J7323	Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose
J7324	Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose
J7325	Hyaluronan or derivative, Synvisc or Synvisc-One, for intra-articular injection, 1 mg
J7326	Hyaluronan or derivative, Gel-One, for intra-articular injection, per dose
J7327	Hyaluronan or derivative, Monovisc, for intra-articular injection, per dose

1–10 of 14

1/2

ICD-10 Diagnosis Codes (referential)ICD-10

M13.0	Polyarthritis, unspecified
M17.0	Bilateral primary osteoarthritis of knee
M17.10	Unilateral primary osteoarthritis, unspecified knee
M17.11	Unilateral primary osteoarthritis, right knee
M17.12	Unilateral primary osteoarthritis, left knee
M17.2	Bilateral post-traumatic osteoarthritis of knee
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee
M17.31	Unilateral post-traumatic osteoarthritis, right knee
M17.32	Unilateral post-traumatic osteoarthritis, left knee
M17.4	Other bilateral secondary osteoarthritis of knee

1–10 of 12

1/2

Applicable HCPCS codes (updated list referenced in Policy History)HCPCS

No codes listed

Provider Actions & Operational Notes

Documentation Required

Use of third-party tools

UnitedHealthcare may use third‑party tools (e.g., InterQual) to assist in administering benefits. Providers should be prepared to supply documentation supporting medical necessity consistent with those tools when requested.

Documentation Required

Reference member-specific benefit plan and mandates

Reference the member‑specific benefit plan document and applicable federal/state mandates when applying this policy. The member-specific plan governs if there is a conflict.

Clinical Evidence & Rationale

Peak 8 wksTherapeutic timeline: effect by 4 wks, peak at 8 wks, residual at 24 wks (Bannuru 2011)

Function benefitModerate-quality evidence: better function vs saline; pain benefit vs corticosteroids inconsistent at 6 months (Hayes 2018)

ECRI: inconclusiveSystematic finding: evidence inconclusive overall; some patients may benefit; optimal formulation/populations uncertain (ECRI 2019)

Vocal fold IL limitedVocal fold injection evidence: small studies show short–medium improvements; limited RCT data and small samples (multiple sources)

Sodium hyaluronate (hyaluronic acid, HA) is a synovial fluid component used as intra-articular viscosupplementation to lubricate joints; commercially prepared products differ by molecular weight and cross-linking and may be derived from bacterial fermentation or avian sources. FDA approvals are limited to treatment of pain due to osteoarthritis of the knee, and no product has consistent evidence of superiority over others.

Systematic reviews and comparative evidence are mixed: ECRI (2019) found evidence inconclusive with some patients getting relief and questions about optimal formulation and populations; Hayes (2018) reported moderate-quality evidence of better function versus saline but inconsistent pain benefit versus corticosteroids at 6 months and no substantive safety differences among products; meta-analyses (Bannuru 2011 and others) indicate efficacy for knee pain with onset by 4 weeks, peak at 8 weeks, and residual effect at 24 weeks though trial quality and heterogeneity limit conclusions.

Definitions

Intra-articular (IA): Injection into the joint space.

Conservative therapy: Non-surgical management including physical therapy, NSAIDs, acetaminophen, topical capsaicin, and/or intra-articular steroids.

Injection Laryngoplasty (IL): Injection of material (e.g., hyaluronic acid) into the vocal fold to improve glottic closure and voice in unilateral vocal fold paralysis/insufficiency.

Viscosupplementation: Intra-articular injection of hyaluronic acid preparations intended to act as a lubricant for osteoarthritis-related joint pain, primarily the knee.

Policy Revision History

01/01/2026revisedLatest

Archived previous policy version IEXD0081.08. Updated list of applicable HCPCS codes to reflect annual edits and revised description for J7322.

Policy Summary

PayerUnitedHealthcare

PolicySodium Hyaluronate – Individual Exchange Medical Benefit Drug Policy

Policy CodePolicy IEXD0081.09

Change TypeRevised HCPCS list / description update

Effective DateJan 1, 2026

Next Review Date

Key ActionMembers on non-preferred products must change therapy to Durolane, Euflexxa, or Gelsyn-3 unless Medical Necessity Criteria are documented.

SourceLink

On This Page

{"text":"Member has a documented history of a trial of adequate dose and duration of Durolane, Euflexxa, and Gelsyn-3 resulting in minimal clinical response.", "note":"Clinical response should be documented in the medical record (e.g., persistent pain, limited function despite therapy)."},

Physician attests that, in their clinical judgment, the clinical response to the non-preferred product would be expected to be superior to that achieved with Durolane, Euflexxa, and Gelsyn-3.

Attestation must include rationale why the non-preferred product is expected to be superior.

{"text":"Member has documented failure, contraindication, or intolerance to Durolane, Euflexxa, and Gelsyn-3.", "note":"Documentation may include adverse reaction history, laboratory evidence, or prior authorization denial for intolerance/contraindication."},

Physician attests that the same failure, contraindication, or intolerance would not be expected to occur with the requested non-preferred product.

Attestation must include clinical rationale and supporting documentation.

Prior Authorization

Product change requirement / prior authorization for non-preferred products

Product change requirement / prior authorization for non-preferred products. Prior authorization is required when requesting coverage for non-preferred sodium hyaluronate products. Requests must document meeting the product-specific medical necessity conditions (trial and response or documented failure/contraindication/intolerance plus physician attestation) described in the Medical Necessity criteria above.

Affected HCPCS/J‑codes: J7320, J7321, J7322, J7323, J7324, J7325, J7326, J7327, J7328, J7329, J7331, J7332
Include clinical documentation of prior trials, intolerances/contraindications, and physician attestation when submitting prior authorization requests.

Billing Rule

Updated HCPCS codes effective 01/01/2026

Updated HCPCS codes effective 01/01/2026. The HCPCS descriptions and code usage have been revised; providers should verify and use the updated J‑codes and descriptions when billing.

Note: J7322 description was revised—confirm the current descriptor and ensure correct code selection.
Refer to the Applicable Codes section of this policy for the full list of sodium hyaluronate J‑codes and their descriptions; verify payer billing requirements and documentation prior to claim submission.

The pain is attributed to degenerative joint disease/primary osteoarthritis of the knee

There are no contraindications to the injections (e.g., active joint infection, bleeding disorder)

Dosing is in accordance with the US FDA approved labeling as shown in the table (FDA labeled dosage per treatment course per joint)

Initial authorization is for a single treatment course once per joint for 6 months (refer to table)Single treatment course for 6 months

Initial authorization duration

Documentation Required

Documentation of conservative therapy and functional impairment

Document the following when requesting coverage for intra-articular sodium hyaluronate for knee OA: diagnosis of knee osteoarthritis; history of inadequate response to conservative therapy OR inability to tolerate conservative therapy (>= 3 months) or intolerance; description of pain that interferes with functional activities; absence of contraindications (e.g., active joint infection, bleeding disorder); and dosing consistent with US FDA labeling.

Diagnosis of knee osteoarthritis
Failed or intolerant conservative therapy ≥ 3 months (or documented inability to tolerate)
Description of functional interference from pain (e.g., ambulation, prolonged standing)
Absence of contraindications to injections (e.g., active joint infection, bleeding disorder)
Dosing per US FDA approved labeling

Documentation Required

Reference member-specific plan and federal/state mandates

When determining coverage, reference the member-specific benefit plan document and applicable federal/state mandates. The member-specific benefit plan governs in the event of a conflict.

Dosing is in accordance with the US FDA approved labeling as shown in the table (FDA labeled dosage per treatment course per joint)

Continuing authorization is for a single treatment course once per joint for 6 months (refer to table)Single treatment course for 6 months

Reauthorization duration

Billing Rule

Dosing per FDA labeling

Dosing and permitted number of injections/courses must follow the US FDA‑approved labeling for each product. Initial and continuing authorization is for a single treatment course once per joint for 6 months; repeated courses require at least 6 months since the prior course.

Authorization: single treatment course once per joint for 6 months
Reauthorization allowed only after ≥ 6 months and with documentation of prior clinical response
Follow FDA labeled dosage per product (see FDA labeling table)

Improve the skin's appearance, contour and/or reduce depressions due to acne, scars, injury, or wrinkles

Cosmetic exclusion - not covered

Denial Risk

Request for non-knee indications

Claims for intra‑articular sodium hyaluronate for hip, temporomandibular joint (TMJ), TMJ disc displacement, or other non‑knee indications are considered unproven and not medically necessary and are subject to denial.

Hip osteoarthritis
Temporomandibular joint osteoarthritis
Temporomandibular joint disc displacement
Other non‑knee indications

Randomized trials and RCT-based reviews show variable results across joints: some RCTs and systematic reviews demonstrate modest benefit for knee OA while evidence for hip, ankle, shoulder, and TMJ is limited or inconsistent and generally considered insufficient to establish efficacy for non-knee indications.

Evidence for vocal fold injection laryngoplasty (injection laryngoplasty, IL) with HA is limited but suggestive: several small studies and prospective series (e.g., Wang et al. 2015) report short- to medium-term improvements in glottic closure and voice measures and that many patients required only a single injection; randomized or high-quality comparative RCT evidence is lacking (Cochrane review found no qualifying RCTs comparing alternative injection materials).

Contraindications include known hypersensitivity to hyaluronate preparations or avian-derived products (not applicable to Orthovisc), hypersensitivity to gram positive bacterial proteins (Orthovisc only), and infection or skin disease at the injection site/joint.

Use of HA preparations for skin contouring, acne, scars, and wrinkle treatment is considered cosmetic and not covered, since these indications are not functionally impairing.

Overall the policy summarizes that HA is FDA-cleared as a device for knee OA with product-specific single- or multi-injection regimens, but clinical trial evidence is variable across products and indications, supporting a targeted, criteria-based coverage approach.